engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered ...
engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered ...
61 8 9443 3011 Website - MLPH Revenue Sorry, this data cannot be displayed at the moment. MLPH Earnings Per Share Sorry, this data cannot be displayed at the moment. Earnings Revisions Sorry, this data cannot be displayed at the moment. ...